BR9811755A - Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica - Google Patents

Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica

Info

Publication number
BR9811755A
BR9811755A BR9811755-6A BR9811755A BR9811755A BR 9811755 A BR9811755 A BR 9811755A BR 9811755 A BR9811755 A BR 9811755A BR 9811755 A BR9811755 A BR 9811755A
Authority
BR
Brazil
Prior art keywords
peptide
animal
pharmaceutical composition
obesity
treatment
Prior art date
Application number
BR9811755-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Frank Man-Woon Ng
Woei-Jia Jiang
Original Assignee
Metabolic Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO9001A external-priority patent/AUPO900197A0/en
Priority claimed from AUPP0398A external-priority patent/AUPP039897A0/en
Application filed by Metabolic Pharmaceutical Ltd filed Critical Metabolic Pharmaceutical Ltd
Publication of BR9811755A publication Critical patent/BR9811755A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Percussion Or Vibration Massage (AREA)
BR9811755-6A 1997-09-08 1998-09-04 Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica BR9811755A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO9001A AUPO900197A0 (en) 1997-09-08 1997-09-08 Treatment of obesity
AUPP0398A AUPP039897A0 (en) 1997-11-13 1997-11-13 Treatment of obesity
PCT/AU1998/000724 WO1999012969A1 (en) 1997-09-08 1998-09-04 Treatment of obesity

Publications (1)

Publication Number Publication Date
BR9811755A true BR9811755A (pt) 2000-08-29

Family

ID=25645599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811755-6A BR9811755A (pt) 1997-09-08 1998-09-04 Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica

Country Status (12)

Country Link
US (2) US6737407B1 (enExample)
EP (1) EP1012189B1 (enExample)
JP (1) JP4334761B2 (enExample)
CN (1) CN1195776C (enExample)
AT (1) ATE377026T1 (enExample)
BR (1) BR9811755A (enExample)
CA (1) CA2303395C (enExample)
DE (1) DE69838647T2 (enExample)
ES (1) ES2296342T3 (enExample)
NZ (1) NZ502993A (enExample)
RU (1) RU2223970C2 (enExample)
WO (1) WO1999012969A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ387599A0 (en) 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005007859A2 (en) * 2003-07-11 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1755637B8 (en) * 2004-05-04 2012-10-03 Metabolic Pharmaceuticals Ltd. Methods for preventing or treating bone disorders
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
US20110092448A1 (en) * 2005-08-02 2011-04-21 Metabolic Pharmaceuticals Limited Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
WO2008098280A1 (en) * 2007-02-16 2008-08-21 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of dicarba bridges in growth hormone peptides
AU2009292651A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of AOD-like peptides
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
KR102148910B1 (ko) * 2011-12-09 2020-08-28 메타볼릭 파마슈티칼즈 피티와이 엘티디 성장 호르몬 단편들의 사용
CN102827290A (zh) * 2012-09-07 2012-12-19 浙江大学 人血清白蛋白与人生长激素脂肪分解结构域的融合蛋白
GB2507341A (en) * 2012-10-29 2014-04-30 Peter Kenny Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone
WO2019136528A1 (en) * 2018-01-15 2019-07-18 Lateral IP Pty Ltd Peptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG49718A3 (bg) 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US4863901A (en) 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity

Also Published As

Publication number Publication date
DE69838647T2 (de) 2008-08-28
ES2296342T3 (es) 2008-04-16
EP1012189A4 (en) 2004-10-20
EP1012189A1 (en) 2000-06-28
WO1999012969A1 (en) 1999-03-18
JP4334761B2 (ja) 2009-09-30
RU2223970C2 (ru) 2004-02-20
DE69838647D1 (de) 2007-12-13
US6737407B1 (en) 2004-05-18
NZ502993A (en) 2002-12-20
CN1195776C (zh) 2005-04-06
JP2002501004A (ja) 2002-01-15
ATE377026T1 (de) 2007-11-15
US20040192608A1 (en) 2004-09-30
CN1275132A (zh) 2000-11-29
CA2303395C (en) 2008-12-02
EP1012189B1 (en) 2007-10-31
CA2303395A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
BRPI9708566A (pt) Análogo de glp-2, análogo de peptìdeo glp-humano, peptìdeo, composição farmacêutica, uso de um análogo de glp-2, e, processo para identificar análogos intestinotróficos de glp-2.
BR9607647A (pt) Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
BR9610331A (pt) Composições farmacêuticas para distribuição nasal de compostos úteis para o tratamento de osteoporose
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
ATE377026T1 (de) Behandlung von fettleibigkeit
EP1234586A3 (en) Hepatoselective pharmaceutical actives
DE69907577D1 (de) Entzündungshemmende Zusammensetzung
ATE220917T1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
ATE100714T1 (de) Arzneimittel (calcitoningen verwandte peptide) zur behandlung erektiler dysfunktionen.
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
PT1001802E (pt) Preparacao farmaceutica combinada compreendendo a hormona da paratiroide e um inibidor de reabsorcao ossea
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
ATE365542T1 (de) Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels
KR880013974A (ko) 합성펩티드와 이를 포함하는 제약학적 조성물
KR960000921A (ko) 칼시토닌 유도체 및 그 용도
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
AU2003292326A1 (en) Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
PT980253E (pt) Somatostatina e agonistas de somatostatina para tratar a insensibilidade a insulina e a sindrome x
PT804182E (pt) Utilizacao de gabapentina para o tratamento da ansiedade e do panico
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.